The report on Drug Discovery Technologies Market by technology type (biochips, high throughput screening, pharmacogenomics, genomics, bioanalytical instruments, bioinformatics, nanotechnology), end users (biopharmaceutical, pharmaceutical, research institutes and biotech companies) trends analysis and forecasts up to 2024 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Drug Discovery Technologies Market is projected to grow at a CAGR of 18.4% in terms of value over the period of 2018-2024. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
The global artificial intelligence (AI) in drug discovery market size is expected to reach USD 4.05 billion by 2028 according to a new study by Polaris Market Research.
Drug discovery informatics is a method which generates large amount of data and information on drug and diseases which is used for research and development.
Global Drug Discovery Informatics Market is expected to rise from its initial estimated value of USD 1.85 billion in 2018 to an estimated value of USD 4.34 billion by 2026, registering a CAGR of 11.27% in the forecast period of 2019-2026. Increasing investment on R&D is driving the growth of this market.
Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics...... @ @ https://bit.ly/3D4dtix
This report studies the global Drug Discovery Services market, analyzes and researches the Drug Discovery Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Drug Discovery Market report 2018-2023 begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Drug Discovery by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
This report studies the global Drug Discovery Services market, analyzes and researches the Drug Discovery Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market
The global artificial intelligence (AI) in drug discovery market is expected to grow from $0.36 billion in 2020 to $0.47 billion in 2021 at a compound annual growth rate (CAGR) of 30.6%.
The global drug discovery informatics market size is expected to reach USD 5.62 billion by 2028 according to a new study by Polaris Market Research. The report “Drug Discovery Informatics Market Share, Size, Trends, Industry Analysis Report, By Workflow (Discovery Informatics, Development Informatics); By Mode (Outsourced, In-house); By Services (Sequence Analysis Platforms, Molecular Modeling, Docking, Clinical Trial Data Management, Others); By Regions; Segment Forecast, 2021 – 2028”
Global drug discovery informatics market was valued approximately US$ 2.0 Bn in 2016 and is anticipated to register CAGR of over 17.0% from 2017 to 2025 to reach value of approximately US$ 7.8 Bn by 2025.
Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals... @@ https://bit.ly/3y2JLrb
The Business Research Company added a report “Artificial Intelligence (AI) In Drug Discovery Market” to its collection – which covers the industry overview with size, share, development, demand and distribution. https://bit.ly/2EcMAyX
Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is anticipated to reach around USD 6.5 billion by 2023. Get more details @ https://goo.gl/UgKpgf
Big Market Research “Global Drug Discovery Informatics Market 2022” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. See Full Report @ bit.ly/1vM6jVN
Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.
The report covers the analysis of global as well as regional markets of Drug Discovery Technologies. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run.
Drug and Gene Delivery Devices Market, by Route of Administration (Oral, Injectables, Transdermal, Topical, Nasal, Inhalation, Ocular), Vector (Virus, Non Virus), Method (In-Situ, Ex-Vivo) - Global Revenue, Trends, Growth, Share, Size, and Forecast to 2022 https://www.scalarmarketresearch.com/request-sample.php?id=644
Bharat Book Present"Pain Therapeutics - Drugs, Markets and Companies"describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain.
A new report on Global Conjunctivitis Drug Industry 2016 Market Research Report seen on DecisionDatabases.com analyses the complete market. The industry sales & production volumes, industry’s trends are all discussed,explained and analysed.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.
Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.
The Business Research Company’s Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022 covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. http://bit.ly/2MO73fb
Bharat Book Bureau provides the report on “Antibacterial Therapies Drug Market”, (https://www.bharatbook.com/healthcare-market-research-reports-842536/antibacterial-therapies-drug-development.html) The report includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Avail more information from Sample Brochure of report @ http://bit.ly/2dlXJ2P The study covers and analyses “Global Mammalian Market”. Bringing out the complete key insights of the industry, the report aims to provide an opportunity for players to understand the latest trends, current market scenario, government initiative and technologies related to the market. In addition, it will help the venture capitalist in understanding the companies better and take informed decisions. Read analysis @ http://bit.ly/2cYaYDP
Analgesics: drug discovery Jenny Laird AstraZeneca Research & Development Montr al Choosing a target for drug discovery should cover an unmet medical need has ...
Increased spending in cancer-related research and development by various governments and private and commercial organizations combined with investments in anti-cancer drugs are the two key factors anticipated to heighten the generic oncology drugs demand, through 2019, as indicated in a recent market analysis of generic oncology drugs, by Persistence Market Research (PMR).
The report provides drug profiles which include product description, MOA, technology, licensors & collaborators, development partner and detailed chemical information.
The market is driven by factors, such as technological advancements and innovations, increasing compliance for drug discovery processes, and high demand for organ and tissue transplantation.
Expanding at a rather high CAGR of nearly 6.7 percent, small molecule generic oncology drugs, combing the efficacies of chemotherapy and immunotherapies could boost the ongoing cancer treatment modalities.
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
Download Sample Brochure @ http://bit.ly/2cUzvLT Cardiovascular Inflammation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. Read Analysis @ http://bit.ly/2dxrN8n
Download Sample Brochure @ http://bit.ly/2dEhRvj DelveInsight’s, “ Xerostomia-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Xerostomia. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Read Analysis @ http://bit.ly/2dwYulS
According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
Analyze Future: Leukemia Treatment Drugs Markets in China To Get More Details @ http://www.analyzefuture.com/leukemia-treatment-drugs-in-china-market China's demand for Leukemia Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.
The biochip market is expected to witness significant growth throughout the forecast period because of an increasing application of biochips in genomics, proteomics and drug discovery.
The global pharmaceutical drugs market was valued around $935 billion in 2017. North America was the largest region in the pharmaceutical drugs market in 2017, accounting for around 37% of the total market. Read Report https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report-2018
The global market for RNAi drug delivery technologies reached nearly $9.3 billion in 2012 and nearly $11.7 billion in 2013. This market is expected to grow to $38.8 billion in 2018, with a compound annual growth rate(CAGR) of 27.2% from 2013 to 2018.
The global metabolic disorder drugs market was valued around $87 billion in 2017. North America was the largest region in the metabolic disorder drugs market in 2017, accounting 53% market share. Read Report https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report-2018
Aptamers is an emerging market, widely considered as a rival or substitute to antibodies in the scientific industry. It is poised to grow rapidly in various application areas, including therapeutics and diagnostics. The global aptamers market is valued at $287 million in 2013 and is expected to reach $2.1 billion by 2018. Aptamers existed in parallel with antibodies for two decades, but its market potential was not utilized, even to a fraction of antibodies. However, the achievement of Macugen has given a boost to the aptamer field. The list of promising aptamers in the clinical trials pipeline estimates that these synthetic chemical antibodies will soon surpass monoclonal antibodies in therapeutics, diagnosis, and imaging. With technological merits over antibodies, the aptamers market is poised to grow at par with antibodies in the next 10-15 years.
Goldstein Research analyst forecast the Metabolomics market size is set to reach USD 2.1 billion by 2024, at a CAGR of 11.3% over the forecast years. With increasing importance being placed on health and safety related aspects of food, metabolomics can potentially be a valuable tool to monitor and improve the quality of what we consume.
The global central nervous system drugs market was valued at around $71 billion in 2017. North America was the largest region in the central nervous system drugs market in 2017, accounting for nearly 40% market share. Read Report https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2018
Get more information about the market: http://bit.ly/2ywjaVx Generic drugs are considered as bioequivalent of branded drugs as they are similar in terms of quality, strength, dosage and intended use. They require low capital investment as they only incur the manufacturing cost without the expenditure on drug discovery, drug development, advertising, distribution of free samples, etc. Want more information about this market? Request a free report sample: https://www.imarcgroup.com/request?type=report&id=549&flag=B Contact Us IMARC Group USA: +1-631-791-1145 Email: sales@imarcgroup.com Website: https://www.imarcgroup.com Follow us on twitter: @imarcglobal
JSB Market Research published latest report titled "Global and USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)" Browse complete report @ http://goo.gl/CYCwde